Home
Our Company
Our Innovation
Our Caring
Our Giving
Media Center
Press Releases
2013-05-01
Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration
2013-04-08
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
2013-03-08
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
2013-03-04
FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Cardiovascular Events in Patients with Acute Coronary Syndrome
2013-02-05
Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
2012-12-12
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
2012-12-05
New Long-Term Study Suggests Lower Mortality in Alzheimer's Patients Treated with Galantamine Versus Placebo
2012-07-10
Janssen Research & Development, LLC, Sponsors First of its Kind Research Initiative to Advance Multiple Sclerosis Science
2012-06-15
Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
2012-05-31
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
Media Center
Newsroom
Press Releases
Archive
Media toolkits
